JP2022546414A5 - - Google Patents

Info

Publication number
JP2022546414A5
JP2022546414A5 JP2022513164A JP2022513164A JP2022546414A5 JP 2022546414 A5 JP2022546414 A5 JP 2022546414A5 JP 2022513164 A JP2022513164 A JP 2022513164A JP 2022513164 A JP2022513164 A JP 2022513164A JP 2022546414 A5 JP2022546414 A5 JP 2022546414A5
Authority
JP
Japan
Prior art keywords
alkyl
independent
halo
deutherium
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022513164A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022546414A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/048621 external-priority patent/WO2021041975A1/en
Publication of JP2022546414A publication Critical patent/JP2022546414A/ja
Publication of JP2022546414A5 publication Critical patent/JP2022546414A5/ja
Pending legal-status Critical Current

Links

JP2022513164A 2019-08-29 2020-08-28 Perk阻害ピロロピリミジン化合物 Pending JP2022546414A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962893528P 2019-08-29 2019-08-29
US62/893,528 2019-08-29
PCT/US2020/048621 WO2021041975A1 (en) 2019-08-29 2020-08-28 Perk inhibiting pyrrolopyrimidine compounds

Publications (2)

Publication Number Publication Date
JP2022546414A JP2022546414A (ja) 2022-11-04
JP2022546414A5 true JP2022546414A5 (cg-RX-API-DMAC7.html) 2023-08-28

Family

ID=72470610

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022513164A Pending JP2022546414A (ja) 2019-08-29 2020-08-28 Perk阻害ピロロピリミジン化合物

Country Status (12)

Country Link
US (1) US20220356186A1 (cg-RX-API-DMAC7.html)
EP (1) EP4021908A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022546414A (cg-RX-API-DMAC7.html)
KR (1) KR20220066290A (cg-RX-API-DMAC7.html)
CN (1) CN114710956A (cg-RX-API-DMAC7.html)
AU (1) AU2020336975A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022003584A2 (cg-RX-API-DMAC7.html)
CA (1) CA3152508A1 (cg-RX-API-DMAC7.html)
IL (1) IL290889A (cg-RX-API-DMAC7.html)
MX (1) MX2022002446A (cg-RX-API-DMAC7.html)
PH (1) PH12022550491A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021041975A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021041973A1 (en) 2019-08-29 2021-03-04 Hibercell, Inc. Perk inhibiting compounds
CA3182276A1 (en) 2020-05-08 2021-12-02 Halia Therapeutics, Inc. Inhibitors of nek7 kinase
CN117597346A (zh) * 2021-04-05 2024-02-23 哈利亚治疗公司 Nek7抑制剂
JP2024513227A (ja) * 2021-04-05 2024-03-22 ハリア・セラピューティクス・インコーポレイテッド Nek7阻害剤
US20240287081A1 (en) * 2021-06-09 2024-08-29 Icahn School Of Medicine At Mount Sinai Perfluoroalkane substituted pyrazolo[3,4-d]pyrimidin and pyrrolo[2,3-d]pyrimidin compounds and uses thereof
US20250000859A1 (en) 2021-08-25 2025-01-02 Alesta Therapeutics BV Use of gcn2 inhibitors in treating cancer
GB202407386D0 (en) 2024-05-24 2024-07-10 Apollo Ap45 Ltd 1H-pyrazolo(4,3-D)pyrimidine derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903297A (en) 1973-11-01 1975-09-02 Upjohn Co Method of treatment and prophylaxis of gastric hypersecretion and gastric and duodenal ulcers using prostaglandin analogs
BR9808281A (pt) * 1997-03-19 2000-05-16 Basf Ag Compostos, composições farmacêuticas, processo para tratar doenças proliferativas e/ou distúrbios do sistema imune e para preparar um composto, e, uso de um composto
US7863444B2 (en) * 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
US8598156B2 (en) 2010-03-25 2013-12-03 Glaxosmithkline Llc Chemical compounds
EP3067356B1 (en) * 2013-11-08 2018-07-04 ONO Pharmaceutical Co., Ltd. Pyrrolo pyrimidine derivative
WO2016004254A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1
WO2016085160A2 (ko) * 2014-11-28 2016-06-02 (주)네오팜 발모촉진용 또는 탈모방지용 조성물
GB201508747D0 (en) * 2015-05-21 2015-07-01 Univ Edinburgh Compounds
WO2017046739A1 (en) * 2015-09-15 2017-03-23 Glaxosmithkline Intellectual Property (No.2) Limited Imidazolidinone derivatives as inhibitors of perk
TW201722957A (zh) * 2015-09-15 2017-07-01 葛蘭素史克智慧財產(第二)有限公司 化學化合物
EP3481831B1 (en) * 2016-07-07 2023-09-06 Daewoong Pharmaceutical Co., Ltd. 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical composition comprising the same
SI3612519T1 (sl) * 2017-04-18 2022-04-29 Eli Lilly And Company Fenil-2-hidroksi-acetilamino-2-metil-fenilne spojine

Similar Documents

Publication Publication Date Title
JP2010531345A5 (cg-RX-API-DMAC7.html)
US20140011798A1 (en) Imidazopyrrolidinone compounds
JP2019517487A5 (cg-RX-API-DMAC7.html)
JP2013544893A5 (cg-RX-API-DMAC7.html)
RU2005119151A (ru) Производные пиридазинона в качестве gsk-3бета-ингибиторов
US20230159514A1 (en) Compositions and methods for inhibiting kinases
RU2017121044A (ru) Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы
BR112012017713A2 (pt) Aminopiridina, formulação farmacêutica, processo para a preparação de um derivado de aminopiridina, intermediário, e, uso de uma aminopiridina ou de uma formulação farmacêutica
JP2000001434A (ja) コルチコトロピン放出因子アンタゴニストを含む医薬組成物
JP2018529770A5 (cg-RX-API-DMAC7.html)
RU2008110913A (ru) НОВЫЕ ПРОИЗВОДНЫЕ ИМИДАЗО[4,5-b]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ ГЛИКОГЕНСИНТАЗЫ 3 ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ДЕМЕНЦИИ И НЕЙРОДЕГЕНЕРАТИВНЫХ РАССТРОЙСТВ
RU2003121307A (ru) (диазоло-пиридинил)-пиримидины для применения в лечении нарушений центральной нервной системы и диабета
US20240245634A1 (en) Pcna inhibitors and egfr inhibitors for cancer treatment
RU2018112993A (ru) Соединения и способы для ингибирования JAK
CA2568608A1 (en) Six membered amino-amide derivatives as angiogenesis inhibitors
CA2803055A1 (en) Heteroaryl compounds and compositions as protein kinase inhibitors
RU2017145928A (ru) МОДУЛЯТОРЫ ROR ГАММА (RORγ)
CN102647986A (zh) 治疗增殖性障碍和其它由bcr-abl、c-kit、ddr1、ddr2或pdgf-r激酶活性介导的病理学病症的方法
JP2023547396A5 (cg-RX-API-DMAC7.html)
WO2013082324A1 (en) Improved modulators of hec1 activity and methods therefor
JP2015131865A (ja) 抗癌用医薬
US20190030009A1 (en) Compounds and compositions for the treatment of cryptosporidiosis
AU2017205389A1 (en) Benzothiazole amphiphiles
CA2564574A1 (en) Use of c-kit inhibitors for treating fibrosis
RU2015101211A (ru) Производное имидазопиридина, используемое для лечения сахарного диабета